Why Valeant CEO Thinks Johnson & Johnson Should Foot The Bill For Their Talc Defense

Published: May 25, 2017

BRIDGEWATER, NJ — When Valeant, the scandal-ridden pharmaceutical giant, acquired Johnson & Johnson’s Shower to Shower body product in 2012, it didn’t foresee being up against more than 30 lawsuits claiming that talc—an ingredient in the product—could cause cancer.

But news broke on May 9 that Valeant believes J&J is obligated to pay for its legal defense and compensate Valeant, according to a transcript of Valeant’s first quarter earnings call.

Back to news